Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
There are no as such competitors for Inhibikase Therapeutics.
Inhibikase Therapeutics has a consensus price target of $6.50.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.06 last updated January 30, 2025 at 5:28 PM EST.
There are no upcoming dividends for Inhibikase Therapeutics.
Inhibikase Therapeutics’s Q4 earnings are confirmed for Wednesday, March 26, 2025.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.